Rapid COVID-19 test developed to detect neutralising antibodies with high specificity and sensitivity

(Duke-NUS Medical School) As the current COVID-19 pandemic continues to adversely impact communities and economies across the world, efficiency in testing for the infection and antibodies is vital. A unique and rapid SARS-CoV-2 surrogate virus neutralisation test (sVNT), developed in Singapore, may be the much needed boost to current COVID-19 investigations to determine infection rate, herd immunity, predicted humoral protection, and vaccine efficacy during clinical trials.